UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 137

Sortiert nach

Mesenchymal stem cell-derived interleukin-28 drives the selection of apoptosis resistant bone metastatic prostate cancer

Nature communications, 2021-02, Vol.12 (1), p.723-723, Article 723

2021

Volltextzugriff (PDF)

Targeting protein tyrosine phosphatases for anticancer drug discovery

Current pharmaceutical design, 2010-06, Vol.16 (16), p.1843

2010

Volltextzugriff (PDF)

GSK3 suppression upregulates β-catenin and c-Myc to abrogate KRas-dependent tumors

Nature communications, 2018-12, Vol.9 (1), p.5154-9, Article 5154

2018

Volltextzugriff (PDF)

ACK1/TNK2 Regulates Histone H4 Tyr88-phosphorylation and AR Gene Expression in Castration-Resistant Prostate Cancer

Cancer cell, 2017-06, Vol.31 (6), p.790-803.e8

2017

Volltextzugriff (PDF)

A Novel Inhibitor of STAT3 Homodimerization Selectively Suppresses STAT3 Activity and Malignant Transformation

Cancer research (Chicago, Ill.), 2013-03, Vol.73 (6), p.1922-1933

2013

Volltextzugriff (PDF)

Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets

Cell chemical biology, 2016-12, Vol.23 (12), p.1490-1503

2016

Volltextzugriff (PDF)

Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity

Proceedings of the National Academy of Sciences - PNAS, 2007-05, Vol.104 (18), p.7391-7396

2007

Volltextzugriff (PDF)

Structural Insights into JAK2 Inhibition by Ruxolitinib, Fedratinib, and Derivatives Thereof

Journal of medicinal chemistry, 2021-02, Vol.64 (4), p.2228-2241

2021

Volltextzugriff (PDF)

Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors

Clinical cancer research, 2019-10, Vol.25 (19), p.5984-5996

2019

Volltextzugriff (PDF)

ACK1 Tyrosine Kinase Interacts with Histone Demethylase KDM3A to Regulate the Mammary Tumor Oncogene HOXA1

The Journal of biological chemistry, 2014-10, Vol.289 (41), p.28179-28191

2014

Volltextzugriff (PDF)

Inhibition of p53 DNA binding by a small molecule protects mice from radiation toxicity

Oncogene, 2020-07, Vol.39 (29), p.5187-5200

2020

Volltextzugriff (PDF)

Potent Dual BET Bromodomain-Kinase Inhibitors as Value-Added Multitargeted Chemical Probes and Cancer Therapeutics

Molecular cancer therapeutics, 2017-06, Vol.16 (6), p.1054-1067

2017

Volltextzugriff (PDF)

Dual Targeting of WEE1 and PLK1 by AZD1775 Elicits Single Agent Cellular Anticancer Activity

ACS chemical biology, 2017-07, Vol.12 (7), p.1883-1892

2017

Volltextzugriff (PDF)

Delving into the reducing effects of the GABAB positive allosteric modulator, KK-92A, on alcohol-related behaviors in rats

Alcohol (Fayetteville, N.Y.), 2023-11, Vol.112, p.61-70

2023

Volltextzugriff (PDF)

The non-canonical target PARP16 contributes to polypharmacology of the PARP inhibitor talazoparib and its synergy with WEE1 inhibitors

Cell chemical biology, 2022-02, Vol.29 (2), p.202-214.e7

2022

Volltextzugriff (PDF)

Ack1-mediated Androgen Receptor Phosphorylation Modulates Radiation Resistance in Castration-resistant Prostate Cancer

The Journal of biological chemistry, 2012-06, Vol.287 (26), p.22112-22122

2012

Volltextzugriff (PDF)

Fendiline Enhances the Cytotoxic Effects of Therapeutic Agents on PDAC Cells by Inhibiting Tumor-Promoting Signaling Events: A Potential Strategy to Combat PDAC

International journal of molecular sciences, 2019-05, Vol.20 (10), p.2423

2019

Volltextzugriff (PDF)

Discovery of a Novel Shp2 Protein Tyrosine Phosphatase Inhibitor

Molecular pharmacology, 2006-08, Vol.70 (2), p.562-570

2006

Volltextzugriff (PDF)

GSK3 Alpha and Beta Are New Functionally Relevant Targets of Tivantinib in Lung Cancer Cells

ACS chemical biology, 2014-02, Vol.9 (2), p.353-358

2014

Volltextzugriff (PDF)

Chronologically modified androgen receptor in recurrent castration-resistant prostate cancer and its therapeutic targeting

Science translational medicine, 2022-06, Vol.14 (649), p.eabg4132

2022

Volltextzugriff (PDF)

Experimental study on mechanical properties of Textile Reinforced Concrete (TRC)

E3S Web of Conferences, 2023, Vol.387, p.4002

2023

Volltextzugriff (PDF)

Integrated proteomics identifies PARP inhibitor-induced prosurvival signaling changes as potential vulnerabilities in ovarian cancer

The Journal of biological chemistry, 2022-11, Vol.298 (11), p.102550-102550, Article 102550

2022

Volltextzugriff (PDF)

Differential Chemoproteomics Reveals MARK2/3 as Cell Migration‐Relevant Targets of the ALK Inhibitor Brigatinib

Chembiochem : a European journal of chemical biology, 2023-06, Vol.24 (11), p.e202200766-n/a

2023

Volltextzugriff (PDF)

Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results

Clinical cancer research, 2021-05, Vol.27 (10), p.2712-2722

2021

Volltextzugriff (PDF)

Dabrafenib inhibits the growth of BRAF‐WT cancers through CDK16 and NEK9 inhibition

Molecular oncology, 2018-01, Vol.12 (1), p.74-88

2018

Volltextzugriff (PDF)

1 – 25 von 137

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(119)
Mit Volltextzugriff
(131)

Publikationsform

Sprache

Englisch
(137)
Japanisch
(19)

Erscheinungsjahr

n.n

Thema

Science & Technology
(74)
Life Sciences & Biomedicine
(59)
Humans
(48)
Cell Line, Tumor
(28)
Animals
(27)
Mice
(23)
Biochemistry & Molecular Biology
(18)
Pharmacology & Pharmacy
(18)
Chemistry, Medicinal
(14)
Antineoplastic Agents - Pharmacology
(13)
Oncology
(13)
Phosphorylation
(13)
Female
(11)
Models, Molecular
(11)
Structure-Activity Relationship
(11)
Antineoplastic Agents
(10)
Biological And Medical Sciences
(10)
Chemistry
(10)
Medical Sciences
(10)
Male
(9)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Mesenchymal stem cell-derived interleukin-28 drives the selection of apoptosis resistant bone metastatic prostate cancer

Targeting protein tyrosine phosphatases for anticancer drug discovery

GSK3 suppression upregulates β-catenin and c-Myc to abrogate KRas-dependent tumors

ACK1/TNK2 Regulates Histone H4 Tyr88-phosphorylation and AR Gene Expression in Castration-Resistant Prostate Cancer

A Novel Inhibitor of STAT3 Homodimerization Selectively Suppresses STAT3 Activity and Malignant Transformation

Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets

Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity

Structural Insights into JAK2 Inhibition by Ruxolitinib, Fedratinib, and Derivatives Thereof

Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors

ACK1 Tyrosine Kinase Interacts with Histone Demethylase KDM3A to Regulate the Mammary Tumor Oncogene HOXA1

Inhibition of p53 DNA binding by a small molecule protects mice from radiation toxicity

Potent Dual BET Bromodomain-Kinase Inhibitors as Value-Added Multitargeted Chemical Probes and Cancer Therapeutics

Dual Targeting of WEE1 and PLK1 by AZD1775 Elicits Single Agent Cellular Anticancer Activity

Delving into the reducing effects of the GABAB positive allosteric modulator, KK-92A, on alcohol-related behaviors in rats

The non-canonical target PARP16 contributes to polypharmacology of the PARP inhibitor talazoparib and its synergy with WEE1 inhibitors

Ack1-mediated Androgen Receptor Phosphorylation Modulates Radiation Resistance in Castration-resistant Prostate Cancer

Fendiline Enhances the Cytotoxic Effects of Therapeutic Agents on PDAC Cells by Inhibiting Tumor-Promoting Signaling Events: A Potential Strategy to Combat PDAC

Discovery of a Novel Shp2 Protein Tyrosine Phosphatase Inhibitor

GSK3 Alpha and Beta Are New Functionally Relevant Targets of Tivantinib in Lung Cancer Cells

Chronologically modified androgen receptor in recurrent castration-resistant prostate cancer and its therapeutic targeting

Experimental study on mechanical properties of Textile Reinforced Concrete (TRC)

Integrated proteomics identifies PARP inhibitor-induced prosurvival signaling changes as potential vulnerabilities in ovarian cancer

Differential Chemoproteomics Reveals MARK2/3 as Cell Migration‐Relevant Targets of the ALK Inhibitor Brigatinib

Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results

Dabrafenib inhibits the growth of BRAF‐WT cancers through CDK16 and NEK9 inhibition

Suchergebnisse filtern